Biofrontera Inc.
BFRI
$1.08
-$0.02-1.82%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 36.16% | -22.46% | 15.19% | 8.54% | 18.53% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 36.16% | -22.46% | 15.19% | 8.54% | 18.53% |
| Cost of Revenue | -42.92% | -58.07% | -39.15% | -20.60% | -1.79% |
| Gross Profit | 93.37% | 19.54% | 82.67% | 40.15% | 39.38% |
| SG&A Expenses | 6.44% | 23.04% | 33.35% | -6.34% | -9.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -12.12% | -5.05% | 9.29% | -1.82% | -1.31% |
| Operating Income | 366.30% | -26.57% | -0.16% | 16.83% | 55.71% |
| Income Before Tax | 503.15% | -17.24% | -2,137.55% | 59.72% | -139.74% |
| Income Tax Expenses | 100.00% | 100.00% | 5.00% | -200.00% | 50.00% |
| Earnings from Continuing Operations | 504.01% | -17.29% | -1,971.60% | 59.73% | -139.59% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 504.01% | -17.29% | -1,971.60% | 59.73% | -139.59% |
| EBIT | 366.30% | -26.57% | -0.16% | 16.83% | 55.71% |
| EBITDA | 375.39% | -29.52% | -2.27% | 15.38% | 55.13% |
| EPS Basic | 362.06% | 37.16% | -1,027.33% | 83.56% | -111.20% |
| Normalized Basic EPS | 329.38% | 37.16% | -1,194.16% | 83.04% | 87.70% |
| EPS Diluted | 362.06% | 37.16% | -1,027.33% | 83.56% | -111.20% |
| Normalized Diluted EPS | 329.38% | 37.16% | -1,194.16% | 83.04% | 87.70% |
| Average Basic Shares Outstanding | 54.17% | 86.64% | 83.67% | 144.89% | 253.49% |
| Average Diluted Shares Outstanding | 54.17% | 86.64% | 83.67% | 144.89% | 253.49% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |